SCHEMBL19967045

SCHEMBL19967045

O=S1(=O)c2ccc(OCc3c(Cl)cccc3Cl)cc2CN1c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 9/20 0.49
▸ FFAR1 O14842 6/20 0.49
▸ S1PR5 Q9H228 3/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ESR1 P03372 1/20 0.40
▸ NR1H4 Q96RI1 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TUBB4A P04350 1/20 0.37
▸ TUBB P07437 1/20 0.37
▸ TUBA3C P0DPH7 1/20 0.37
▸ TUBA1B P68363 1/20 0.37
▸ TUBA4A P68366 1/20 0.37
▸ TUBB4B P68371 1/20 0.37
▸ TUBB3 Q13509 1/20 0.37
▸ TUBB2A Q13885 1/20 0.37
▸ TUBB8 Q3ZCM7 1/20 0.37
▸ TUBA3E Q6PEY2 1/20 0.37
▸ TUBA1A Q71U36 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19967182 0.84 FFAR1 (0.64) FFAR4FFAR1
SCHEMBL19967144 0.79 FFAR4 (0.60) FFAR4FFAR1ESR1
SCHEMBL19967187 0.78 FFAR1 (0.53) FFAR4FFAR1
SCHEMBL19967146 0.78 FFAR4 (0.65) FFAR4FFAR1
SCHEMBL21168484 0.76 FFAR4 (0.75) FFAR4FFAR1
SCHEMBL19967183 0.75 ESR1 (0.53) FFAR4FFAR1ESR1MEN1KMT2A
SCHEMBL19967157 0.73 FFAR4 (0.74) FFAR4FFAR1
SCHEMBL19967065 0.71 FFAR4 (0.50) FFAR4FFAR1SMN1; SMN2
SCHEMBL19967184 0.69 FFAR4 (0.52) FFAR4FFAR1
SCHEMBL7483584 0.66 SMN1; SMN2 (0.69) SMN1; SMN2NR1H4MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3509588-B1 BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS INTEGRAL HEALTH INC (US) 2023-06-07 — — EP disclosed
US-20210347768-A1 BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS VALO HEALTH, INC. 2021-11-11 — — US disclosed
US-10865201-B2 Bicyclic compounds useful as GPR120 modulators VALO HEALTH, INC. (US) 2020-12-15 — — US disclosed
US-20190218208-A1 BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS VALO HEALTH, INC. 2019-07-18 — — US disclosed
WO-2018049328-A1 BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS NUMERATE, INC. (US) 2018-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10865201-B2 Bicyclic compounds useful as GPR120 modulators GPR119, GPR180, GPR65 FFAR4 38/4885FFAR1 20/4885S1PR5 642/4885
US-20190218208-A1 BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS GPR119, GPR180, GPR65 FFAR4 38/4885FFAR1 20/4885S1PR5 642/4885
US-20210347768-A1 BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS GPR119, GPR180, GPR65 FFAR4 38/4885FFAR1 20/4885S1PR5 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback